The Journey of Amlodipine

Amlodipine besylate is absorbed slowly and completely from the
gastrointestinal tract with a bioavailability of approximately 60-65%. Unlike some other calcium
channel blockers, it does not undergo significant presystemic (first-pass) hepatic metabolism.
Peak plasma concentrations are reached 6-12 hours after oral dosing — unusually delayed, reflecting
amlodipine's very slow intestinal absorption rate. Absorption is not significantly affected by
food. The slow absorption profile, combined with amlodipine's high volume of distribution and
extremely long half-life, produces remarkably stable plasma levels with once-daily dosing, avoiding
the peaks and troughs that can cause reflex tachycardia with shorter-acting dihydropyridines like
nifedipine. This gentle pharmacokinetic profile directly translates to smooth antihypertensive
action and better tolerability.

Amlodipine is extensively protein-bound (approximately 97-98%
to albumin) and has a very large volume of distribution (21 L/kg), indicating extensive tissue
accumulation. It distributes preferentially to peripheral vascular smooth muscle, cardiac muscle,
and myocardium. The drug accumulates in the membranes of vascular smooth muscle cells, where it
associates with L-type calcium channels in their inactive (resting) state. Plasma concentrations
are low relative to tissue concentrations. Amlodipine crosses the placenta but fetal exposure
data are limited. It is not significantly distributed to the CNS.

Amlodipine blocks L-type (long-lasting, CaV1.2) voltage-gated
calcium channels in vascular smooth muscle and cardiac muscle. The dihydropyridine binding site
is located within the channel pore on transmembrane segments IIIS5-IIIS6, distinct from the
phenylalkylamine (verapamil) and benzothiazepine (diltiazem) binding sites. Amlodipine binds
preferentially to the inactivated state of the channel (state-dependent blockade), and its
uncharged structure at physiological pH allows it to reach the binding site via the lipid bilayer
as well as the open channel. Once bound, channel opening probability is reduced and calcium
influx during depolarization is attenuated. In vascular smooth muscle, this reduces intracellular
calcium, decreasing the calcium-calmodulin-MLCK-mediated phosphorylation of myosin light chain,
causing relaxation and vasodilation. The drug acts predominantly on peripheral resistance
arterioles, reducing systemic vascular resistance and afterload. It has minimal negative inotropic
and chronotropic effects at therapeutic doses because vascular smooth muscle has a more depolarized
resting membrane potential, promoting inactivated-state selectivity.

Amlodipine is extensively metabolized by CYP3A4 (and to a lesser
extent CYP3A5) in the liver to pharmacologically inactive pyridine metabolites. Approximately
90% of the drug is converted to metabolites, none of which retain significant calcium channel
blocking activity. CYP3A4 inducers (rifampicin, St John's wort) can significantly reduce
amlodipine exposure, while CYP3A4 inhibitors (itraconazole, clarithromycin) can increase
concentrations. The long half-life means it takes approximately 7-10 days to reach steady state
or for drug levels to substantially fall after dose adjustment.

Metabolites are excreted primarily in urine (approximately 60%),
with the remainder in feces. Renal excretion of unchanged amlodipine is minimal (less than 10%).
Plasma half-life is 30-50 hours in healthy adults and can extend to 56-65 hours in elderly patients
or those with hepatic impairment (since metabolism is the rate-limiting elimination step). This
extended half-life means that once-daily dosing provides smooth, sustained antihypertensive effect
with less than 10% peak-to-trough variation in plasma levels.

Amlodipine is a first-line antihypertensive with proven mortality
benefit in the ASCOT and ACCOMPLISH trials. Its long half-life makes it particularly forgiving
of missed doses. Unlike diltiazem and verapamil, it can be safely combined with beta-blockers.
Peripheral edema (ankle edema) occurs in up to 10-15% of patients — this is a hemodynamic side
effect (precapillary vasodilation without matching postcapillary dilation) rather than fluid
retention, and does not respond to diuretics but may improve with ACE inhibitor combination.
It has minimal drug interactions compared to diltiazem/verapamil because it does not inhibit CYP3A4.